Hyoungjoo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyoungjoo Lee has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Caraballo
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 7
22 shared publications - Alice E. Shin
Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, USA
22 shared publications - Andrew T. Chan
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
22 shared publications - Carmen Rios
Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Boston, Massachusetts. 10
22 shared publications - Chi-Lee C. Ho
Department of Surgery, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York. 1
22 shared publications - Daniel C. Chung
Massachusetts General Hospital 1 Division of Gastroenterology Boston, Massachusetts
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 3 shows the progression of disease between 4and 8 week old TCON mice and the amount of ACTN4 and DPP4 in stomach tissue.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 1 shows the effect using different lysis buffers has on protein identification in stool protein mass spectrometry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 2 describes the biopsy information of patient derived organoid cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Table 1 lists the age and sex of stool donors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 4 contains heat maps of stool proteins between various stool donor groups and emphasizes the differential abundance of protein profiles based on donor status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- Open Access
Seed structure and phosphorylation in the fuzzy coat impact tau seeding competency
Tau is a pathogenic protein in Alzheimer’s (AD) and other neurodegenerative diseases. The misfolding of tau into β-sheet rich elongated filaments is thought to be a key event in disease pathogenesis, followed by subsequent templated recruitment of monomeric tau into this pathogenic form. Cryo-electron microscopy has revealed that specific tau conformations characterize different diseases. In this study, we explored how tau filament core structure and post-translational modifications in its disordered fuzzy coat influence its seeding capacity in primary neurons and mice. We show that the structure of the seeds affects seeding capacity, but that the AD tau core structure alone is insufficient to capture the full seeding capacity of AD tau. Proteolytic cleavage of AD tau which removes the fuzzy coat causes a loss in seeding capacity, as does removal of phosphorylation from the fuzzy coat by phosphatase treatment. Re-phosphorylation of phosphatase-treated AD tau by kinase treatment partially restores seeding activity. Finally, we find that filaments of recombinant tau with twelve phospho-mimetic residues (PAD12 tau) with the AD fold are able to recapitulate the seeding capacity of AD tau. Combined, these results suggest that the structure of the ordered core, together with phosphorylation in the fuzzy coat, confers the seeding capacity of tau filaments.
Open AccessSeed structure and phosphorylation in the fuzzy coat impact tau seeding competency
Tau is a pathogenic protein in Alzheimer’s (AD) and other neurodegenerative diseases. The misfolding of tau into β-sheet rich elongated filaments is thought to be a key event in disease pathogenesis, followed by subsequent templated recruitment of monomeric tau into this pathogenic form. Cryo-electron microscopy has revealed that specific tau conformations characterize different diseases. In this study, we explored how tau filament core structure and post-translational modifications in its disordered fuzzy coat influence its seeding capacity in primary neurons and mice. We show that the structure of the seeds affects seeding capacity, but that the AD tau core structure alone is insufficient to capture the full seeding capacity of AD tau. Proteolytic cleavage of AD tau which removes the fuzzy coat causes a loss in seeding capacity, as does removal of phosphorylation from the fuzzy coat by phosphatase treatment. Re-phosphorylation of phosphatase-treated AD tau by kinase treatment partially restores seeding activity. Finally, we find that filaments of recombinant tau with twelve phospho-mimetic residues (PAD12 tau) with the AD fold are able to recapitulate the seeding capacity of AD tau. Combined, these results suggest that the structure of the ordered core, together with phosphorylation in the fuzzy coat, confers the seeding capacity of tau filaments.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 2 contains stomach immunofluorescence images for Figure 3B.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Stool Protein Mass Spectrometry Identifies Biomarkers for Early Detection of Diffuse-type Gastric Cancer
Supplemental Figure 5 shows the effect of S1P pathway lipids on GC cell lines without the presence of C6-U-Cer inhibition.